Gamida Cell Ltd.

OTCPK:GMDA.Q Stock Report

Market Cap: US$2.6m

Gamida Cell Management

Management criteria checks 2/4

Gamida Cell's CEO is Abbey Jenkins, appointed in Sep 2022, has a tenure of 1.67 years. total yearly compensation is $1.36M, comprised of 41.8% salary and 58.2% bonuses, including company stock and options. directly owns 0.38% of the company’s shares, worth $9.89K. The average tenure of the management team and the board of directors is 2.9 years and 4.9 years respectively.

Key information

Abbey Jenkins

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage41.8%
CEO tenure1.7yrs
CEO ownership0.4%
Management average tenure2.9yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Gamida Cell shares slide after stock offering

Sep 27

Gamida appoints Emergent’s former head of vaccines as new CEO

Sep 19

Gamida Cell Q2 2022 Earnings Preview

Aug 12

Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel

Aug 01

Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?

Feb 23
Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?

Gamida Cell: Recapping A Tough Year

Nov 02

Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?

Nov 02
Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?

CEO Compensation Analysis

How has Abbey Jenkins's remuneration changed compared to Gamida Cell's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$62m

Dec 31 2023US$1mUS$571k

-US$63m

Sep 30 2023n/an/a

-US$77m

Jun 30 2023n/an/a

-US$93m

Mar 31 2023n/an/a

-US$80m

Dec 31 2022US$707kUS$157k

-US$79m

Compensation vs Market: Abbey's total compensation ($USD1.36M) is above average for companies of similar size in the US market ($USD661.07K).

Compensation vs Earnings: Abbey's compensation has increased whilst the company is unprofitable.

CEO

Abbey Jenkins (47 yo)

1.7yrs

Tenure

US$1,364,308

Compensation

Ms. Abigail L. Jenkins, M.S. also known as Abbey, serves as a Director at XORTX Therapeutics Inc. since April 08, 2024. She is Independent Director of Aquestive Therapeutics, Inc. from April 1, 2024. She i...

Leadership Team

NamePositionTenureCompensationOwnership
Abigail Jenkins
President1.7yrsUS$1.36m0.38%
$ 9.9k
Mary Coelho
Chief Financial Officerless than a yearUS$1.06mno data
Ronit Simantov
Chief Medical Officer & Chief Scientific Officer6.8yrsUS$1.34m0.33%
$ 8.7k
Linda Stamler
Vice President of Marketing & Account Management3.3yrsno datano data
Penny Bushell
Chief Human Resource Officer1.5yrsno datano data
Naftali Brikashvili
Senior Vice President Finance & Operationsno datano datano data
Tracey Lodie
Scientific Advisor & Consultant2.8yrsno datano data
Vladimir Melnikov
Senior Vice President of Global Operations & Manufacturing2.9yrsno datano data
Heather DiVecchia
Chief of Staffno datano datano data
Rocio Manghani
Senior Vice President of Market Access3.5yrsno datano data
Kelly Randis
Head of Global Information Technologyno datano datano data

2.9yrs

Average Tenure

55.5yo

Average Age

Experienced Management: GMDA.Q's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Abigail Jenkins
President1.7yrsUS$1.36m0.38%
$ 9.9k
Kenneth Moch
Independent Director7.8yrsUS$179.77k0.10%
$ 2.7k
Stephen Wills
Independent Director4.9yrsUS$213.10k0.12%
$ 3.2k
Julian Adams
Director7.8yrsUS$865.34k0.89%
$ 23.4k
Shawn Tomasello
Independent Chairwoman4.9yrsUS$209.17k0.11%
$ 2.8k
Ivan Borrello
Independent Director1.9yrsUS$161.86k0.070%
$ 1.8k

4.9yrs

Average Tenure

65yo

Average Age

Experienced Board: GMDA.Q's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/26 03:15
End of Day Share Price 2024/05/24 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gamida Cell Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew CrossAlliance Global Partners
Matthew LuchiniBMO Capital Markets Equity Research
Vernon BernardinoH.C. Wainwright & Co.